⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31673078 | 0.93 | — | — | |
| SCHEMBL4410177 | 0.93 | — | — | |
| SCHEMBL28302428 | 0.91 | HPGD (0.35) | — | |
| SCHEMBL2002222 | 0.76 | EPHX1 (0.42) | — | |
| SCHEMBL3370950 | 0.76 | — | — | |
| SCHEMBL18541673 | 0.76 | — | — | |
| SCHEMBL2152919 | 0.76 | — | — | |
| SCHEMBL18541742 | 0.76 | — | — | |
| SCHEMBL1399166 | 0.76 | — | — | |
| SCHEMBL6545557 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-112521387-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3784670-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-9688669-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688669-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688669-B2 | Oxazolidinones as modulators of mGluR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160237072-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| CN-101309900-B | Substituted cycloalkene derivative | DAIICHI SANKYO CO LTD | 2015-04-22 | — | — | CN | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| CN-102333760-B | Halogen-containing organosulfur compounds and use thereof for controlling arthropod pest | SUMITOMO CHEMICAL CO | 2014-04-09 | — | — | CN | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| CN-101309900-A | Substituted cycloalkene derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-19 | — | — | CN | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |